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In Brief
Blinova et al. tested human-induced
pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs) for
improving torsades de pointes
arrhythmia risk prediction of drugs in the
Comprehensive In Vitro Proarrhythmia
Assay (CiPA) initiative. This validation
study confirms their utility based on
electrophysiologic responses to 28
blinded drugs, with minimal influence
from cell lines, test sites, and
electrophysiological platforms.
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https://doi.org/10.1016/j.celrep.2018.08.079SUMMARY
To assess the utility of human-induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CMs) as
an in vitro proarrhythmia model, we evaluated the
concentration dependence and sources of variability
of electrophysiologic responses to 28 drugs linked to
low, intermediate, and high torsades de pointes
(TdP) risk categories using two commercial cell lines
and standardized protocols in a blinded multisite
study using multielectrode array or voltage-sensing
optical approaches. Logistical and ordinal linear
regression models were constructed using drug
responses as predictors and TdP risk categories as
outcomes. Three of seven predictors (drug-induced
arrhythmia-like events and prolongation of repo-3582 Cell Reports 24, 3582–3592, September 25, 2018
This is an open access article under the CC BY-NC-ND license (http://larization at either maximum tested or maximal clin-
ical exposures) categorized drugs with reasonable
accuracy (area under the curve values of receiver
operator curves 0.8). hiPSC-CM line, test site, and
platform had minimal influence on drug categoriza-
tion. These results demonstrate the utility of hiPSC-
CMs to detect drug-induced proarrhythmic effects
as part of the evolving Comprehensive In Vitro Proar-
rhythmia Assay paradigm.INTRODUCTION
Fourteen drugs have been removed from the market worldwide
as a result of their potential to induce a rare but potentially fatal
ventricular arrhythmia, torsades de pointes (TdP) (Stockbridge
et al., 2013). The International Council on Harmonisation (ICH)creativecommons.org/licenses/by-nc-nd/4.0/).
adopted two guidelines on the assessment of drug-induced TdP
(ICH S7B and ICH E14) that outline the assessment of the poten-
tial of new pharmaceuticals to delay ventricular repolarization in
in vitro assays, including testing for their ability to block the
human ether-a-go-go-related (hERG) potassium channel, and
in vivo, to prolong the QT interval on the electrocardiogram.
Adoption of these guidelines has been effective in preventing
new drugs with unrecognized TdP risk from reaching themarket;
however, the current regulatory approach lacks specificity,
because multiple drugs block hERG or prolong the QT interval
but have a low risk of TdP. It is possible that overemphasis on
hERG block and QT prolongation in proarrhythmic potential
assessment has prevented some useful and safe drugs from
reaching the market. The Comprehensive In Vitro Proarrhythmia
Assay (CiPA) initiative represents a new paradigm to improve the
specificity of proarrhythmic risk assessment (Fermini et al., 2016;
Sager et al., 2014). The non-clinical aspects of CiPA rely on a
mechanistic assessment of drug effects on cellular electrophys-
iology (EP) using (1) in silico reconstruction of human ventricular
electrical activity based on drug effects on multiple human
ionic currents, each expressed in heterologous expression
systems, and (2) assessment of drug effects in human-induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to
detect any missed or unanticipated EP effects (Food and Drug
Administration, 2017).
The use of hiPSC-CMs for cardiac safety evaluation of the
new drug candidates continues to increase, as evidenced by
numerous recent publications. Many of these studies demon-
strate the ability of hiPSC-CMs as model systems to detect
EP effects of drugs, including delayed or altered repolarization
(Blinova et al., 2017; Clements and Thomas, 2014; Yamamoto
et al., 2016). While encouraging, such studies typically use small
test sets; different cellular preparations, protocols, and experi-
mental endpoints; inconsistent criteria to interpret results; and
different gold standards related to either delayed repolarization
or proarrhythmic risk. Such differences hinder cross-site com-
parisons of data and recognition of sources of experimental
variability. A significant step forward was made recently (Ando
et al., 2017; Yamamoto et al., 2016), in which a large set of drugs
was evaluated at multiple sites following a standardized exper-
imental protocol; however, that study was limited to the evalua-
tion of a single cell line and one EP platform used across sites
with no statistical modeling of results. Comprehensive evalua-
tions using multiple sites, interrogation techniques, and cell
sources are necessary because all models have limitations
that may appear under different circumstances. Despite pos-
sessing nearly identical underlying early after depolarization
(EAD) properties as traditionally accepted models (e.g., mature
canine ventricular cardiomyocytes [Ma et al., 2011]), hiPSC-
CMs are often described as having fetal or neonatal ion channel
and ionic current stoichiometries (Jonsson et al., 2012; Sala
et al., 2017) that may interfere with the accurate prediction of
proarrhythmic risk.
To characterize the potential utility of hiPSC-CMs within the
CiPA paradigm, the present study was conducted to charac-
terize, in blinded fashion, the EP effects of 28 drugs with known
clinical TdP risk on hiPSC-CMs using 2 commercially available
hiPSC-CM lines tested across 10 experimental sites and 5 EPplatforms. Specifically, this validation study focused on (1) char-
acterization of site-to-site variability of the assessment of EP
effects of the drugs using either microelectrode array (MEA) or
voltage-sensing optical (VSO) techniques and standardized
protocols to assess drug-induced altered repolarization, and
(2) identification of important hiPSC-CM assay endpoints asso-
ciated with high, intermediate, and low TdP risk using linear
regression models. The present study builds upon on a previous
smaller pilot study that evaluated the EP effects of 8 drugs using
MEA approaches and 4 positive controls across a smaller
number of sites (Millard et al., 2018). Overall, the conceptual
advance of this work is not in the discovery or the development
of a new iPSC-CMs-based assay, but rather in performing
a first large-scale multisite study combining MEA and VSO
techniques to evaluate the current state of iPSC-CM-based
assays in the assessment of drug-induced TdP.
RESULTS
Electrophysiological Effects Induced in hiPSC-CMs by
Drugs with Known Risk Levels for Clinical TdP Risk
Ten independent sites used a standardized protocol to evaluate
the EP effects of 28 drugs with known levels of clinical risk cate-
gorized by expert consensus (Colatsky et al., 2016) into 3 clinical
TdP risk groups (high, intermediate, and low or no risk) (Fermini
et al., 2016) (see Table S1 for details on experimental sites,
protocols, and platforms and Table S2 for drug categories
and concentrations). Fifteen complete datasets, including data
from 5 sites that studied drug effects on both iCell cardiomyo-
cytes2 and Cor.4U cardiomyocytes (referred to here as iCell2
and Cor.4U cells), were analyzed. Drug-induced repolarization
prolongation (baseline and vehicle-controlled, rate-corrected
action potential duration at 90% repolarization, ddAPD90c, or
field potential duration, ddFPDc, depending on the EP platform
used; see Experimental Procedures) was measured along with
drug-induced arrhythmias of different types (Figure 1) or drug-
induced cessation of hiPSC-CMs’ spontaneous beating (i.e.,
quiescence).
Low TdP Risk Category
The 9 drugs in the low TdP risk category were verapamil, diltia-
zem, loratadine, metoprolol, mexiletine, nifedipine, nitrendipine,
ranolazine, and tamoxifen. hiPSC-CM responses to verapamil
for all 10 sites is shown in Figure 2, and corresponding figures
for the rest of the low-risk drugs are shown in Supplemental
Data S1. No verapamil-induced repolarization prolongation or
arrhythmias were observed at any concentrations studied.
Diltiazem, loratadine, nifedipine, nitrendipine, and tamox-
ifen did not induce any arrhythmias or statistically significant
repolarization prolongation at concentrations up to 20- to 140-
fold clinical Cmax. The remaining 3 drugs (ranolazine, metopro-
lol, and mexiletine) induced repolarization prolongation and
arrhythmias atR1 of the concentrations in several datasets.
Ranolazine is a known hERG blocker (Crumb et al., 2016)
at clinical concentrations and produces QT prolongation.
Consistent with this, 13 of 15 datasets show statistically
significant ranolazine-induced repolarization prolongation at
concentrations between 0.1- and 5.0-fold Cmax, but noCell Reports 24, 3582–3592, September 25, 2018 3583
Figure 2. EP Effects of Verapamil (Low TdP Risk) across 10 Sites (15
Site/Cell Combinations)
Panel titles represent site number followed by a three-letter code of EP
platform used (AXN, Maestro [Axion BioSystems]; CLY, CellOPTIQ [Clyde
Biosciences]; ECR, CardioECR [ACEA Biosciences]; AMD, AlphaMED64
[Alpha MED Scientific]; and MCS, MEA2100 [Multichannel Systems]). Drug-
induced repolarization prolongation (black and gray circles for Cor.4U and
iCell2, correspondingly, left y axis) are shown as averaged baseline- and
vehicle-controlled, Fridericia rate-corrected ddFPDc/ddAPD90c. Error bars
represent SEs. The bars represent the percentage of wells in which a particular
arrhythmic or quiescent event was observed (see color legend). ddFPDc/
APD90c was not calculated for the drug concentrations in which R50% of
the wells included in the analysis were arrhythmic after drug addition.
Drug concentrations (in mM and x-fold above free [unbound] clinical
Cmax values) are shown in the table on the bottom of the figure, along with
the concentration intervals.
See also Data S1.
Figure 1. Representative Traces of Four Cellular Arrhythmia-Like
Events Recorded in hiPSC-CMs
Recorded by (left) MEA and (right) VSO platforms. The horizontal scale bar
equals 1 s. We refer to type A arrhythmia as a ‘‘mild’’ arrhythmia-like event in
the text.ranolazine-induced arrhythmias. At the highest studied concen-
tration, 100 mM, or >50-fold Cmax, 6 of 15 datasets show
ranolazine-induced arrhythmia-like events or cessation of spon-
taneous beating (9 of 15 datasets) in at least 2 experimental
wells.
Metoprolol is a beta-1 blocker that slows heart rate clinically
and is not associated with TdP risk. In hiPSC-CMs, where
beta-blockade does not occur due to the absence of sympa-
thetic innervation, metoprolol-induced arrhythmias occurred at
100 mM (55-fold Cmax) in 5 datasets and at 31.6 mM (18-fold
Cmax) in 1 dataset, which is consistent with metoprolol-induced
hERG block at higher concentrations (drug concentration for
50% block [IC50] = 145 mM) (Kawakami et al., 2006). Finally,
10 mM mexiletine (4-fold Cmax) induced arrhythmias in 3 of
15 datasets and mexiletine-induced cessation of spontaneous
beating at the highest concentration (100 mM, 40-fold Cmax)
in 12 of 15 datasets.
Intermediate TdP Risk Category
The 11 drugs in the intermediate TdP risk category were terfena-
dine, astemizole, chlorpromazine, cisapride, clarithromycin, clo-
zapine, domperidone, droperidol, ondansetron, pimozide, and
risperidone. hiPSC-CM response to terfenadine for all 10 sites
is shown in Figure 3, and corresponding figures for the other in-
termediate risk drugs are shown in Supplemental Data S2. None
of the sites observed terfenadine-induced arrhythmia-like events
in hiPSC-CMs, even at concentrations as high as 350-fold Cmax,
but terfenadine-induced repolarization prolongation occurred in
11 of 15 datasets.
Statistically significant repolarization prolongation atR1 stud-
ied concentrations was observed in a minimum of 10 of 15 data-
sets for all of the drugs in the intermediate-risk category but
clozapine and chlorpromazine. Clozapine- and chlorproma-3584 Cell Reports 24, 3582–3592, September 25, 2018zine-induced prolongation was reported in only 1 and 3 of
15 of the datasets, respectively. Drug-induced arrhythmia-like
events at any concentration were observed in at least 10 of
15 datasets for all of the intermediate-risk drugs, except for
chlorpromazine, clozapine, terfenadine, and risperidone (0–2
datasets of 15 contained arrhythmia events for these 4 drugs).
High TdP Risk Category
The 8 drugs in the high TdP risk category were dofetilide, azimi-
lide, bepridil, D,L-sotalol, disopyramide, ibutilide, quinidine, and
Figure 3. EP Effects of Terfenadine (Intermediate TdP Risk) across
10 Sites (15 Site/Cell Combinations)
See Figure 2 legend. A star represents datawith number of replicate wells N < 5.
See also Data S2.
Figure 4. Effects of Dofetilide (High TdP Risk) across 10 Sites
(15 Site/Cell Combinations)
See Figure 2 legend. Stars represent missing data or data with number of
replicate wells N% 5.
See also Data S3.vandetanib. The hiPSC-CM response to dofetilide for all 10 sites
is shown in Figure 4, and corresponding figures for the other
high-risk drugs are shown in Supplemental Data S3. Statisti-
cally significant dofetilide-induced repolarization prolongation
or dofetilide-induced arrhythmia-like events were consistently
(14 of 15 datasets) observed in the studied drug concentration
range (0.16- to 5-fold Cmax).
All of the drugs in this category except bepridil induced statis-
tically significant repolarization prolongation and/or arrhythmia-
like events in both hiPSC-CM lines in at least 10 of 15 datasets.
While bepridil-induced statistically significant repolarization
prolongation was reported in 8 of 15 datasets, only 2 data-
sets contained bepridil-induced arrhythmia-like events. Drug-
induced arrhythmia-like events were consistently observed at
concentrations close to clinical Cmax for dofetilide, quinidine,
and D,L-sotalol and at concentrations well below Cmax for ibu-
tilide. Some of the drugs in this category were so potent and the
chosen concentration escalation rate was so steep (i.e., loga-
rithmic increase) that there were no detectable drug effects at
one of the studied concentrations, and then at the next concen-
tration, all of the hiPSC-CMs demonstrated arrhythmia-likeevents, preventing reliable measurement of repolarization
duration.
Minimal Effect of Site-to-Site Variability on Drug-
Induced ddFPDc/APD90c
Despite significant efforts to apply consistent experimental
protocols across sites, minor deviations were noted (see
Table S1 for the experimental protocol deviations for each
site). Site-to-site variability in drug-induced ddFPDc/APD90c
averaged across all 28 drugs was compared to other sources
of variability by treating site effects as either fixed or random
effects (Table S3) and using the square root of the mean
squared error (SR MSE) for each contribution. When site effect
was treated as a fixed effect, SR MSE introduced by site
(170 ms) was lower than variability induced by the hiPSC-CM
line (245 ms). As expected, both values were lower than the
contribution provided by drug concentration (482 ms). Simi-
larly, if site effects were treated as random effects, the vari-
ability in drug-induced ddFPDc or ddAPD90c averaged over
28 drugs introduced by the site was lower than the totalCell Reports 24, 3582–3592, September 25, 2018 3585
Figure 5. Three Significant Model Predic-
tors for Model 1 Shown for All 28 Drugs
Each data point represents individual dataset (site/
cell type combination, 15 datasets total).
(A) Predictor 1, drug-induced arrhythmia-like
event at any concentration (none, no arrhythmias;
type A, only arrhythmia type A; other, any other
arrhythmia type: B, C, D, or any combination ofR2
arrhythmia types).
(B) Predictor 4, maximum observed drug-induced
repolarization prolongation or shortening (ddFPDc
or ddAPD90c) at all studied drug concentrations.
(C) Predictor 7, estimated drug-induced repolari-
zation prolongation or shortening (ddFPDc or
ddAPD90c) at clinical Cmax.random variability from all of the other sources of random
variability (36 versus 67 ms), including well-to-well variability,
plate-to-plate variability, human error, and other sources of
variability.
Modeling of Drug Proarrhythmic Potential Based on Its
hiPSC-CM Effects
Data on the EP effects of 28 drugs with a known clinical risk of
TdP obtained from all of the experimental sites were used to
construct a model that would predict TdP risk category of a
drug based on its effects on hiPSC-CMs. Seven endpoints
from hiPSC-CM experiments were used as potential model
predictors (Table S4). Predictors 1 and 2 describe the ability of
a drug to induce arrhythmia-like events in hiPSC-CMs; predic-
tors 3 and 4 reflect the amount of drug-induced repolarization
prolongation (ddFPDc or ddAPD90c) at the lowest concentration
at which statistically significant change from the baseline (pre-
dictor 3) or maximum prolongation at any of the studied concen-
trations (predictor 4) was observed; predictors 5 and 6 account
for concentrations of a drug relative to its clinical Cmax when
prolongation of FP/AP duration (predictor 5) or arrhythmia-like3586 Cell Reports 24, 3582–3592, September 25, 2018event (predictor 6) were first observed;
predictor 7 is an estimated amount
of prolongation that a drug would
induce at the clinical Cmax (Experimental
Procedures).
Logistic regression models were used
in the regression of risk group (high or in-
termediate risk versus low risk [model 1],
and high risk versus low risk and interme-
diate risk versus low risk [model 2]) on all
7 risk predictors. Cluster analysis showed
that the pairs of predictors 3 and 4 (Pear-
son correlation = 0.52) and predictors 5
and 6 (Pearson correlation = 0.65) are
highly correlated, so 1 of each pair may
be redundant (data not shown). The final
fitted models included 3 significant pre-
dictors: predictor 1, predictor 4, and pre-
dictor 7. Figure 5 shows significant model
predictors for all of the sites for each
drug. hiPSC-CM type (iCell2 or Cor.4U)was not significant (p = 0.089) and did not improve overall fitting
for model 1, but it showed a slight improvement in fitting for
model 2 by decreasing the Akaike information criterion (AIC)
value from 705.3 to 703.2, where AIC is an estimator or the rela-
tive quality of statistical models (for a given set of data, smaller
value indicates better fit):
LogitðP1Þ= ðPredictor1Þ+ ðPredictor4Þ+ ðPredictor7Þ (1)
LogitðP2aÞ= ðCell TypeÞ+ ðPredictor1Þ+ ðPredictor4Þ
+ ðPredictor7Þ (2)
LogitðP2bÞ= ðCell TypeÞ+ ðPredictor1Þ+ ðPredictor4Þ
+ ðPredictor7Þ (3)
where Logit(P) = log(P/(1P)), P1 is a probability of a drug to be of
high or intermediate TdP risk in model 1 and P2a and P2b are
probabilities of a drug to be of high versus low or intermediate
versus low TdP risk in model 2, respectively. Detailed model
parameters are shown in Table S5. Averaged across sites, risk
Figure 6. Model 1 (Dichotomous Model) Prediction of a Drug’s TdP
Risk Category to Be Either Low or Intermediate and High Combined
Averaged from All 10 Sites (15 Cell Type/Platform Combinations)
Error bars represent 95% confidence intervals. Red dotted line represents the
0.8 threshold discussed in the text.
Figure 7. Model 2 Prediction of a Drug to Fall into Low, Intermediate,
or High TdP Risk Category Averaged across 10 Sites (15 Cell Type/
Platform Combinations)
Error bars represent 95% confidence intervals.probabilities predicted by models 1 and 2 are shown in Figures 6
and 7, respectively. An example of model 1 and model 2 predic-
tion is provided in Figure S1. Model 1 prediction fitted through
the data of all of the sites had an area under the receiver oper-
ating characteristic (ROC) curve (AUC) value of 0.872 (Figure S2).
As expected for a model with 3 outcomes, model 2 AUC had a
lower value of 0.826 (Figure S2). Concordance indices (Somers’
deltas [Somers’ D], a measure of ordinal association between
possibly dependent random variables, values from 1 to 1,
with higher values indicating better quality of model prediction)
calculated for models 1 and 2 were 0.74 and 0.65, respectively,
showing good discriminating utility for both models.
Figure 6 can be used to illustrate the potential role of hiPSC-
CMs as a high-specificity preclinical assay under CiPA. By
setting a threshold of low TdP risk versus high or intermediate
TdP risk at 0.8 in model 1 (Figure 6), the predicted TdP risk of
all of the drugs in the low-risk category fall below the
threshold, providing a user with reasonable confidence that
no unanticipated effects were missed for a drug. The one
exception is ranolazine, for which the upper confidence inter-
val (CI) of its estimated risk crosses the 0.8 threshold. As
has been shown before (Blinova et al., 2017), the TdP risk of
drugs that have significant late sodium current effects (e.g., ra-
nolazine) may not be adequately modeled by existing hiPSC-
CMs. Model 1 risk prediction fell below the 0.8 threshold for
1 drug from the high TdP risk category (bepridil) and 4 drugs
from the intermediate drug risk category (risperidone, terfena-
dine, chlorpromazine, and clozapine), highlighting the limita-
tions of the current hiPSC-CMs assays that are not developed
to be used as a stand-alone assay, but can be useful whencombined with other CiPA preclinical proarrhythmia assess-
ment strategies.
Model Validation
The purpose of model validation is to estimate the performance
of a model when applied for a new, independent dataset. One
approach would be to split the data into training and validation
sets, so one may use the training dataset to develop the model
and then apply the model to the validation dataset to measure
the performance. This approach usually requires a large sample
size to avoid significant power loss for modeling. In the present
study, due to the limited sample size, we have performed model
validation and calibration using two alternative methods: cross-
validation and bootstrapping. Both approaches allow for nearly
unbiased estimates of future model performance, assuming
that the present study sample represents a true random
sampling of the population of interest. For cross-validation, the
original data are randomly divided into k equally sized subsam-
ples, then one subsample is used as the validation dataset, while
the remaining subsamples are used as training data. The cross-
validation process is then repeated k times for each subset.
The k results then are averaged to produce a single estimation.
Here, k = 10 was used for the cross-validation process. Similarly,
bootstrapping uses re-sampling with the replacement from
the original dataset, so theoretically, an infinite number of sam-
ples from one set of data can be generated. For both methods,
if the analysis from re-sampling produces results that
are consistent with the original analysis, then the model isCell Reports 24, 3582–3592, September 25, 2018 3587
considered to be reliable and expected to perform for a new, in-
dependent dataset. For model 1, bootstrapping with 500 runs of
re-sampling negligibly reduced the AUC, from 0.872 to 0.865.
Similarly, cross-validation of model 1, omitting from the
model 10% of all observations at a time, minimally reduced
the AUC, from 0.872 to 0.862. Both results demonstrate
the high reliability of model 1. For model 2, bootstrapping with
500 runs of re-sampling negligibly reduced the AUC value,
from 0.819 to 0.808, demonstrating a robust model. Model vali-
dation results suggest that they would be practical, even when
used by a single site applying one of the tested EP platform
and cell type combinations. The experimental design used in
the statistical models does not provide sufficient power to eval-
uate differences in the performance of the EP platforms or iPSC-
CMs lines.
DISCUSSION
This study summarizes results of the first large multisite study
assessing the potential of 2 commercially available hiPSC-CMs
using in vitro-based MEA and VSO approaches to detect drug-
induced repolarization abnormalities and predict the proarrhyth-
mic potential of 28 drugs characterized for TdP risk under
the CiPA initiative. Concentration-dependent effects from 7 EP
responses were used to build 2 regression models that predict
low, intermediate, or high clinical TdP risk categories. The
most useful predictors were identified in the study: (1) the ability
of a drug to induce ‘‘mild’’ (type A) or ‘‘severe’’ (all other)
arrhythmia-like events at any concentration (predictor 1); (2)
the extent of drug-induced repolarization prolongation at any
concentration (predictor 4); and (3) the extent of drug-induced
prolongation at the clinical Cmax (predictor 7). We found it inter-
esting that the ability of a drug to inhibit hiPSC-CMs’ sponta-
neous beating or any of the other predictors did not further
improve model prediction.
Despite the variations in the experimental protocols, including
intended range of the tested EP platforms (5 different platforms;
both MEA and VSO were used) and some unintended variations
in cell batch, recording medium composition, and other param-
eters (Table S1), the results for all 28 drugs were fairly consistent
across 10 sites. Table S6 shows the results of Pearson correla-
tion analysis for drug-induced ddFPDc/APD90c change across
10 sites. Lower coefficient values for individual sites can be
achieved by greater or lesser responses to drugs. Data from
most of the sites were highly correlated (average Pearson coef-
ficients of 78%–88%), while sites 2 and 4 had lower correlation
coefficients (69%and 70%, respectively), potentially for different
reasons because the Pearson coefficient between these 2 sites
is low (37%). Differences observed for site 2 may be attributed to
the differences in experimental protocols, because site 2 was the
only test site that used the VSO platform instead of theMEA plat-
forms and serum-free experimental medium instead of serum-
containing medium. APD90 (VSO) and FPD (MEA) are equivalent
measures, and site 2 showed appropriate APD changes and
arrhythmia-like events in response to drugs, including dofetilide.
However, the absence of serum in the assaymedia used by site 2
and the known potential of serum components (e.g., albumen) to
modulate the bioavailability of some drugs in the serum-contain-3588 Cell Reports 24, 3582–3592, September 25, 2018ing media of all of the other sites (Ando et al., 2017; Schocken
et al., 2018) has the potential to explain the slightly lower average
Pearson coefficient. In contrast, site 4 used experimental proto-
cols that were largely consistent with other MEA sites, including
the use of serum-containing media (Table S1), but overall corre-
lation for that site was lower. Of note, Figure 4 shows that unlike
all of the other sites, site 4 did not report large effects induced by
dofetilide (no significant ddFPDc prolongation or drug-induced
arrhythmia-like events). It will be critical to include positive
drug controls (with known ion channel effects) on each
plate to demonstrate suitable assay sensitivity based on the
predominant mechanisms for affecting repolarization. It is
important to recognize that the model demonstrates the ability
of hiPSC-CMs across sites to detect delayed repolarization
and predict TdP risk for 15 datasets for 28 drugs, but that an
individual site may not be expected to detect the proarrhythmic
risk for each drug.
Furthermore, despite different reprogramming and differentia-
tion protocols used tomanufacture the two hiPSC-CM lines used
in the study, they were similar in predicting intermediate versus
low or low versus high- or intermediate-risk drugs, which is the
current unmet need. However, it is important to note that this
study was limited to two hiPSC-CM lines and that other lines
will require their own validation. Furthermore, the drugs can be
potentially tested in gender-specific or even subject-specific
hiPSC-CMs when feasible for the intended drug target popula-
tion, but for this study we focused on a general assessment of
a molecule, so the choice was made to use well-characterized,
commercially developed hiPSC-CMs lines.
It is important to examine the outlier drugs that induced effects
in hiPSC-CMs that are noticeably different from the other drugs
in the same TdP risk category. Unlike other high-risk drugs and
consistent with previous studies (Blinova et al., 2017), bepridil
did not induce arrhythmias in hiPSC-CMs, even at 30-fold
Cmax (except for 1 of 15 datasets). Bepridil is a potent hERG
blocker that also blocks L-type calcium and peak and late
sodium currents at higher concentrations (Crumb et al., 2016).
High expression levels of calcium ion channels in hiPSC-CMs
as compared to primary ventricular tissue (Blinova et al., 2017)
may have contributed to more attenuated cellular proarrhythmic
effects of the drug as compared to other drugs in the high TdP
risk category. It is also possible that the known propensity of
bepridil to induce cardiac arrhythmia in the clinic is at least partly
related to the ability of bepridil to affect hERG surface expression
(Obejero-Paz et al., 2015). hERG trafficking effects of drugs
were not assessed in this study because of the short duration
exposures of hERG. Another outlier drug was low TdP risk rano-
lazine, which induced significant repolarization prolongation
and arrhythmias in hiPSC-CMs, uncharacteristic for this risk
category. While ranolazine blocks the hERG potassium channel
and prolongs QTc, it is not associated with TdP risk because
hERG block is balanced by significant late sodium current
block (Johannesen et al., 2016). Lower expression levels of
sodium channels and decreased late sodium current in hiPSC-
CMs compared to primary human ventricular tissue (Blinova
et al., 2017; Lemoine et al., 2017) may contribute to the apparent
proarrhythmic effects of ranolazine in hiPSC-CMs. Similarly,
lower densities of late sodium current in hiPSC-CMsmay explain
mexiletine-induced arrhythmia-like events. Finally, another
low-risk drug that induced arrhythmia-like events in hiPSC-
CMs was metoprolol, a beta-blocker, the effects of which
may not be appropriately modeled in uninnervated hiPSC-CMs
monocultures.
The differences in cellular electrophysiology between native
tissue and iPSC-cardiomyocytes has been well documented
(Gibson et al., 2014; Hoekstra et al., 2012; Ma et al., 2011),
with iPSC-cardiomyocytes possessing, in general, spontaneous
activity, depolarized membrane potential (Vm), slower AP up-
stroke, and longer APD and FPD. It is unclear how these
differences would translate into systematic or class-specific
misclassifications, but it does speak to the need for specific
calibration controls demonstrating assay sensitivity for sodium,
calcium, and potassium currents blockade. Relative differences
in ion channel and current levels in iPSC-CMs as compared to
adult ventricular myocytes are likely the most important factors
to improve the accurate prediction of TdP risk, especially with
multichannel blocking drugs. With the development of new
biotechnologies aimed at the development of more adult-like
hiPSC-CMs (Wanjare and Huang, 2017; Yang et al., 2014), the
predictivity of hiPSC-CMs assays is expected to further improve.
Furthermore, other predictors of proarrhythmia risk may be
added to the model based on their ability to differentiate drugs
from the three categories examined here. For example, triangu-
lation of the cardiac AP has previously been correlated with the
ability to cause TdP experimentally (Hondeghem et al., 2001).
Measurements of AP triangulation (corrected for AP duration)
based on data from the VSO platform were correlated with
TdP risk category (Figure S3) and may prove to be a useful
additional descriptor in the future. As demonstrated here,
hiPSC-CMs are an important new human in vitro model for the
assessment of TdP risk, and their role in CiPA should be
considered along with the recent advances in in silico modeling
to predict proarrhythmic cardiotoxicity (Li et al., 2017; Passini
et al., 2017). Computer models of TdP risk based on experimen-
tally measured multichannel drug effects show high predictivity
and would be an important primary step in proarrhythmic risk
assessment, at least until iPSC-CMs become even better
representations of adult human cardiac myocytes. The advan-
tages of using readily available human-derived cardiomyocyte
preparations need to be considered along with comparisons of
the accuracy of cardiomyocytes (versus ex vivo or in vivo animal
models) in predicting proarrhythmic risk when defining the
optimal role of hiPSC-CMs in drug discovery.
Several experimental limitations of the study are worth noting.
First, the free drug concentrations in hiPSC-CM experiments
were not measured. As shown in Table S7, several drugs (e.g.,
disopyramide, azimilide, clarithromycin) were reported by multi-
ple (but not all) sites as being poorly soluble in DMSO at the
required concentrations. Thus, additional measures were taken,
such as sonicating, warming at 37C, or increasing the DMSO
percentage. It has been shown (Schocken et al., 2018) that
serum content in the cell culture medium used for drug dilution
could affect drug solubility and availability. Although all of the
sites followed the same nominal set of drug preparation instruc-
tions, measurements of drug concentrations in the experimental
wells were not performed. Second, this study does not allow forthe measurement of the effect of drug metabolites, which can in
some cases be more toxic than the parent drug (e.g., the metab-
olite of astemizole, desmethylastemizole [Vorperian et al., 1996]).
Third, measuring the effects of hERG blockers on FPD can be
challenging for some drugs because of the decrease in repolar-
ization T-wave amplitude, in addition to the drug-induced
FPD prolongation. Fourth, the effects of only short exposures
(30 min) of drugs were assessed in this study, while some non-
acute proarrhythmic effects (not the emphasis of CiPA) may
require longer exposures to affect channel expression. Finally,
this study was not statistically powered to investigate the effect
of the electrophysiological device on the hiPSC-CM assay’s
predictivity of proarrhythmic drug potential. Table S8 contains
information on the fraction of drugs correctly characterized into
a TdP risk category from the data stratified by the EP platform.
However, these data should be interpreted with caution because
the study design does not allow for distinguishing the effects of
the specific device from other effects introduced by the cell
type or by the experimental site itself. Further studies are needed
to investigate whether device choice would be an important
consideration in improving preclinical TdP risk assessment by
hiPSC-CM-based assays.
In summary, this study used statistical modeling to identify the
most predictive endpoints of hiPSC-CMs assays in TdP risk
assessment. Using only 3 endpoints, model 1 separated drugs
into low-risk versus combined intermediate- and high-risk cate-
gories with an AUC value of 0.87 (87% predictivity) at the sample
size we used, regardless of the type of hiPSC-CM used; model 2
separated drugs into 3 separate risk categories and showed a
slightly lower AUC value of 0.82. Different thresholds with each
model, which have associated sensitivity and specificity values,
can be selected based on when the assay is being used in drug
development. Because the goal of CiPA is to increase specificity
and hiPSC-CMs will be used to check for missed or unantici-
pated effects, a threshold with a high specificity will be required.
For example, a threshold of 0.8 in model 1 is associated with a
specificity of 0.89 and a sensitivity of 0.63. If a drug is predicted
to have a low risk in the in silico TdP risk metric, but is positive at
this threshold, then it could be important to understand the
reason for this discrepancy. If the drug has low proarrhythmic
risk due to balanced multi-ion channel block, such as ranolazine
with both hERG and late sodium current block, then this discrep-
ancy would not be surprising. Such a result should not hinder
progressing with clinical development, in which drug-induced
QT prolongation and signs of balanced ion channel block (no
J-Tpeak prolongation [Johannesen et al., 2016]) would still be
assessed in first-in-human studies. Thus, it will be important to
perform an integrated risk assessment, taking into account the
different components of CiPA when implementing CiPA to
improve specificity and provide more accurate predictions of
clinical TdP risk, rather than solely focusing on hERG block
and QT prolongation.EXPERIMENTAL PROCEDURES
Study Sites and Platforms
Ten independent laboratories participated in the study, using any 1 of the 4
MEA platforms: Maestro (Axion BioSystems, abbreviated to ‘‘AXN’’ in thisCell Reports 24, 3582–3592, September 25, 2018 3589
paper), CardioECR (ACEA Biosciences, ‘‘ECR’’), Multiwell (Multichannel Sys-
tems, ‘‘MCS’’), and AlphaMED64 (Alpha MED Scientific, ‘‘AMD’’), or the VSO
platform: CellOPTIQ (Clyde Biosciences, ‘‘CLY’’).
hiPSC-CMs
Two commercially available hiPSC-CM cell lines were used: iCell2 (Cellular
Dynamics International) andCor.4U (NCardia). iCell2 arenormally cryopreserved
at approximately day 30of thedifferentiation (similar toMaet al. [2011]); the pro-
duction procedures for Cor.4U were not disclosed by the manufacturer. Sites
were instructed to follow manufacturers’ recommendations for hiPSC-CM
plating and maintenance, including cell culture plate coating, cell plating den-
sities, and assay time window. Spontaneously beating, 100% confluent iPSC-
CMs monolayers were used for drug testing. Table S1 contains information on
the specific cell lots, cell-handling details, and variations by experimental site.
Drug Dilution and Addition
Blindeddrugpowderwassent toallof thesitesby theChemotherapeuticAgents
Repository of theNational Cancer Institute, and stored at20Cuntil the day of
testing. Four concentrations of each drug were studied (Table S2). Four DMSO
stocks for each drug concentrationwere prepared and either used on the same
day or aliquoted and frozen. Concentrated (103) testing solutions (503 for
sequential dosing) for each concentration were prepared freshly on the day of
testing by diluting DMSO stocks into experimental medium (serum-containing
maintenancemediumforMEAexperimentsandserum-freemediumforVSOex-
periments; see the hiPSC-CM section for more details). Ten-fold dilution was
achievedwhendrugswere added to theexperimentalwell to attain the targeted
concentration. For sequential dosing, DMSO concentrations were adjusted
sequentially up to 0.1% at the highest concentration to achieve the targeted
concentration of each drug. If insoluble compound was observed in DMSO or
103 testing stock solutions, then warming to 37C and sonicating for 20 min
was recommended. Table S7 contains information on when these measures
were taken to improve drug solubility.
MEA and VSO Recordings of Drug-Induced Effects in hiPSC-CMs
All MEA and VSO recordings were performed at 37C. Single concentrations
of each drug were tested in each experimental well by all of the sites, except
site 10, where sequential additions were used. A 100% media change was
performed in hiPSC-CMs 2–24 hr before baseline recordings. Media composi-
tions used forMEAandVSO recordingsare shown inTableS1.Concentration ef-
fects of each drugwere recorded inR5 replicates for 97% of the collected data.
Experimental points collectedwith <5 replicates aremarkedwith a star in Figures
3 and 4 and in Supplemental Data S1, S2, and S3. Vehicle (0.1%DMSO) control
wells were included on each plate. After baseline recording and drug addition,
the plates were left to re-equilibrate for at least 30 min before recordings.
Data Analysis
Data Exclusion Criteria
The results were excluded from the analysis if baseline parameters for a
specific well were outside the following pre-specified quality standards: (1)
hiPSC-CMs baseline spontaneous beating rate had to be within the 20–90
beats per min range (i.e., 0.3–1.5 Hz), (2) the baseline beating rate had to
be within 6 SDs calculated for the baseline beating rate on all of the wells
on the given plate, (3) the coefficient of variation for the baseline beat
period had to be <5%, and (4) the depolarization spike amplitude had to
be >0.3 mV (MEA recordings only). Based on these criteria, no more than
3% of wells were excluded from analysis.
Drug-Induced Changes in Repolarization and Arrhythmia-like
Events
Fridericia’s formula (Fridericia, 2003) was used to correct hiPSC-CMaction po-
tential duration (APD) and field potential duration (FPD) dependence on beating
rate (APDc, FPDc). While not thoroughly validated for hiPSC-CMs, this formula
is widely used in these assays (Blinova et al., 2017; Clements and Thomas,
2014; Ando et al., 2017; Yamamoto et al., 2016). Baseline- and vehicle-
controlled ddFPDc and ddAPD90c at 90% repolarization were calculated by
averagingall DMSO-treatedwells on theplate for vehicle control.Drug-induced
arrhythmia-like eventswere countedandclassified in 1of 4categories (A–D), as
illustrated in Figure 1. The relation between hiPSC-CMs action potential and3590 Cell Reports 24, 3582–3592, September 25, 2018field potential, including correspondence between different arrhythmia-like
events recorded by MEA and VSO, have been described previously (Asakura
et al., 2015). Combination of events (e.g., AB, AC, ABC, ABCD) was also
observed and recorded. Several drugs inhibited spontaneoushiPSC-CMscon-
tractions, leading to a quiescent state (Q). MEA and VSO instrument operators
were blinded to the drug treatment during data collection and analysis.
Statistical Methods
Descriptive Analysis
The primary measurement was the averaged baseline- and vehicle-controlled,
Fridericia rate-corrected ddFPDc/ddAPD90c at each concentration. Drug
concentrations were treated as ordinal variables, in which the order mattered
but not the difference between concentration values. ddFPDc/APD90c was
not calculated and was designated as missing for the drug concentrations in
whichR50% of the wells were arrhythmic after dosing. The concentration ef-
fects of each drug were recorded in R5 replicates for 97% of the collected
data. Arrhythmia was a binary outcome and was designated as ‘‘Yes’’ if it
occurred in at least one well at any concentration.
Modeling and Model Validation
Seven endpoints characterizing drug responses on hiPSC-CMs were used to
build a linear regression model predicting the drug TdP risk category
(Table S4). For the model development, drug-induced repolarization prolon-
gation in hiPSC-CMs recorded with the MEA platform (ddFPDc) and the VSO
platform (ddAPD90c) was considered equivalent. Cell type was treated as a
fixed effect and experimental site was treated as a random effect in these
models. The predictor selection procedure was based on model-fitting diag-
nostics of the AIC, the Bayesian information criterion (BIC), the AUC, and
cluster analysis among continuous predictors. Model validation was
achieved through cross-validation and bootstrapping. Statistical analysis
was done using SAS (SAS Institute, Cary, NC) and R (RStudio, Boston,
MA) software.
DATA AND SOFTWARE AVAILABILITY
Raw data from this study is available on the CiPA website: http://cipaproject.
org/data-resources/
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, eight tables, and three data
files and can be found with this article online at https://doi.org/10.1016/j.
celrep.2018.08.079.
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